Tag: ovarian cancer
ImmunoGen Submits Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer
Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...
STRO-002 Shows 33% Objective Response Rate in Patients with Advanced Ovarian...
Folate receptor alpha (FolRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as a target for...
ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...
Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...
ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study...
Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...
ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...
Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...
Phase I Dose Escalation Study with Mersana’s XMT-1592 Doses First Patient
Clinical-stage biopharmaceutical company Mersana Therapeutics has confirmed that a first patient has been dosed in a Phase I dose-escalation study evaluating XMT-1592.
XMT-1592 is the...
Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation...
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet...
ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...
The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...
Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...
Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...
Treatment with Siamab ST1 Inhibits Growth of Chemoresistant Ovarian Tumor Cells...
Patients diagnosed with ovarian cancer may have persistent, refractory or recurrent cancer following treatment with surgery and first-line chemotherapy. Generally, persistent cancer refers to...
